{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T22:59:34Z","timestamp":1768258774396,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T00:00:00Z","timestamp":1374019200000},"content-version":"vor","delay-in-days":442,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100006083","name":"Ministry of Defence","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.virol.2012.01.038","type":"journal-article","created":{"date-parts":[[2012,2,15]],"date-time":"2012-02-15T01:05:36Z","timestamp":1329267936000},"page":"100-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["A humanised murine monoclonal antibody protects mice from Venezuelan equine encephalitis virus, Everglades virus and Mucambo virus when administered up to 48 h after airborne challenge"],"prefix":"10.1016","volume":"426","author":[{"given":"Lyn M.","family":"O'Brien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah A.","family":"Goodchild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Phillpotts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart D.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2012.01.038_bb0005","doi-asserted-by":"crossref","first-page":"762","DOI":"10.4269\/ajtmh.1967.16.762","article-title":"Live, attenuated Venezuelan equine encephalomyelitis virus vaccine. I. Clinical effects in man","volume":"16","author":"Alevizatos","year":"1967","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.virol.2012.01.038_bb0010","first-page":"209","article-title":"Attenuation of Venezuelan equine encephalomyelitis virus by in vitro cultivation in guinea pig heart cells","volume":"73","author":"Berge","year":"1961","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.virol.2012.01.038_bb0015","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(00)01034-5","article-title":"Therapeutic monoclonal antibodies","volume":"355","author":"Breedveld","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2012.01.038_bb0020","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/00000441-200206000-00004","article-title":"Viral agents as biological weapons and agents of bioterrorism","volume":"323","author":"Bronze","year":"2002","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.virol.2012.01.038_bb0025","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/tera.1420360303","article-title":"TC-83 Venezuelan equine encephalitis vaccine exposure during pregnancy","volume":"36","author":"Casamassima","year":"1987","journal-title":"Teratology"},{"key":"10.1016\/j.virol.2012.01.038_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2011.01.010","article-title":"A humanised murine monoclonal antibody with broad serogroup specificity protects mice from challenge with Venezuelan equine encephalitis virus","volume":"90","author":"Goodchild","year":"2011","journal-title":"Antiviral Res."},{"key":"10.1016\/j.virol.2012.01.038_bb0035","first-page":"233","article-title":"Circumventing immunogenicity in the development of therapeutic antibodies","volume":"12","author":"Holgate","year":"2009","journal-title":"IDrugs"},{"key":"10.1016\/j.virol.2012.01.038_bb0040","doi-asserted-by":"crossref","first-page":"5558","DOI":"10.1016\/j.vaccine.2010.06.038","article-title":"A recombinant humanized monoclonal antibody completely protects mice against lethal challenge with Venezuelan equine encephalitis virus","volume":"28","author":"Hu","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2012.01.038_bb0045","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1099\/vir.0.81925-0","article-title":"A humanised murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus","volume":"87","author":"Hunt","year":"2006","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virol.2012.01.038_bb0050","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1371\/journal.pntd.0000739","article-title":"The first human epitope map of the Alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutralising activity","volume":"4","author":"Hunt","year":"2010","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.virol.2012.01.038_bb0055","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.virol.2011.03.016","article-title":"Treatment of mice with human monoclonal antibody 24h after lethal aerosol challenge with virulent Venezuelan equine encephalitis virus prevents disease but not infection","volume":"414","author":"Hunt","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.virol.2012.01.038_bb0060","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2005.01.001","article-title":"Immunogenicity of engineered antibodies","volume":"36","author":"Hwang","year":"2005","journal-title":"Methods"},{"key":"10.1016\/j.virol.2012.01.038_bb0065","first-page":"79","article-title":"Venezuelan equine encephalitis","volume":"18","author":"Johnson","year":"1974","journal-title":"Adv. Vet. Sci. Comp. Med."},{"key":"10.1016\/j.virol.2012.01.038_bb0070","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/nbt1363","article-title":"The growth and potential of human antiviral monoclonal antibody therapeutics","volume":"25","author":"Marasco","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.virol.2012.01.038_bb0075","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1016\/j.vaccine.2010.02.056","article-title":"Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus","volume":"28","author":"Martin","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2012.01.038_bb0080","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.virusres.2006.02.003","article-title":"Venezuelan equine encephalitis virus complex-specific monoclonal antibody provides broad protection, in murine models, against airborne challenge with viruses from serogroups I, II and III","volume":"120","author":"Phillpotts","year":"2006","journal-title":"Virus Res."},{"key":"10.1016\/j.virol.2012.01.038_bb0085","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/S0264-410X(98)00315-6","article-title":"TC-83 vaccine protects against airborne or subcutaneous challenge with heterologous mouse-virulent strains of Venezuelan equine encephalitis virus","volume":"17","author":"Phillpotts","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2012.01.038_bb0090","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S0264-410X(01)00505-9","article-title":"Monoclonal antibody protects mice against infection and disease when given either before or up to 24h after airborne challenge with virulent Venezuelan equine encephalitis virus","volume":"20","author":"Phillpotts","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2012.01.038_bb0095","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.vaccine.2004.06.056","article-title":"Intranasal immunisation with defective Adenovirus serotype 5 expressing the Venezuelan equine encephalitis virus E2 glycoprotein protects against airborne challenge with virulent virus","volume":"23","author":"Phillpotts","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2012.01.038_bb0100","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1016\/S0264-410X(03)00328-1","article-title":"Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models","volume":"21","author":"Pratt","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2012.01.038_bb0105","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2337\/diab.25.7.623","article-title":"Virus-induced pancreatic disease by Venezuelan encephalitis virus. Alterations in glucose tolerance and insulin release","volume":"25","author":"Rayfield","year":"1976","journal-title":"Diabetes"},{"key":"10.1016\/j.virol.2012.01.038_bb0110","doi-asserted-by":"crossref","first-page":"10682","DOI":"10.1128\/JVI.05032-11","article-title":"The role of the blood brain barrier during Venezuelan equine encephalitis virus infection","volume":"85","author":"Sch\u00e4fer","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2012.01.038_bb0115","first-page":"879","article-title":"Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy","volume":"45","author":"Schroff","year":"1985","journal-title":"Cancer Res."},{"key":"10.1016\/j.virol.2012.01.038_bb0120","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1177\/0300985810372508","article-title":"Review paper: pathology of animal models of alphavirus encephalitis","volume":"47","author":"Steele","year":"2010","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.virol.2012.01.038_bb0125","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1359-6446(05)03638-X","article-title":"Elimination mechanisms of therapeutic monoclonal antibodies","volume":"11","author":"Tabrizi","year":"2006","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.virol.2012.01.038_bb0130","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.4049\/jimmunol.174.6.3187","article-title":"Rationally engineered therapeutic proteins with reduced immunogenicity","volume":"174","author":"Tangri","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.virol.2012.01.038_bb0135","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s007050050363","article-title":"Humane endpoints are an objective measure of morbidity in Venezuelan encephalomyelitis virus infection of mice","volume":"143","author":"Wright","year":"1998","journal-title":"Arch. Virol."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682212000852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682212000852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:15:31Z","timestamp":1758586531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682212000852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0042682212000852"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2012.01.038","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A humanised murine monoclonal antibody protects mice from Venezuelan equine encephalitis virus, Everglades virus and Mucambo virus when administered up to 48h after airborne challenge","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2012.01.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2012 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}